Q-Pan H1N1

Q-Pan H1N1 is a monovalent, inactivated, split-virion pandemic influenza vaccine developed by GSK. It is specifically manufactured at GSK's facility in Québec, Canada, and is the basis for the brand-named vaccine Arepanrix. The vaccine contains the hemagglutinin (HA) antigen from the A/California/7/2009 (H1N1)v-like virus strain. It is typically formulated with GSK's proprietary AS03 adjuvant system, an oil-in-water emulsion containing squalene, which enhances the immune response and allows for dose sparing of the viral antigen. Q-Pan H1N1 was extensively studied during the 2009 H1N1 pandemic, including Phase II trials in pediatric and adolescent populations to evaluate safety and immunogenicity. It is immunologically equivalent to the D-Pan H1N1 vaccine (Pandemrix) manufactured in Germany.

Brand names

Arepanrix

Other names

A/California/7/2009 (H1N1)v-like vaccineAS03-adjuvanted H1N1 vaccineAS-03-adjuvanted H1N1 vaccineAS 03-adjuvanted H1N1 vaccineMonovalent A/California/7/2009 (H1N1)v-like Q-Pan H1N1 vaccine